Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$3.62M Buy
30,300
+20,537
+210% +$2.69M 0.03% 442
2025
Q4
$1.33M Sell
9,763
-98
-1% -$14.1K 0.01% 706
2025
Q3
$1.45M Buy
9,861
+3,865
+64% +$536K 0.01% 673
2025
Q2
$776K Buy
5,996
+674
+13% +$81.6K 0.01% 843
2025
Q1
$636K Buy
5,322
+1,979
+59% +$245K 0.01% 903
2024
Q4
$388K Sell
3,343
-10,713
-76% -$1.35M 0.01% 1069
2024
Q3
$1.9M Buy
14,056
+9,684
+222% +$1.3M 0.05% 402
2024
Q2
$593K Sell
4,372
-2,486
-36% -$338K 0.02% 797
2024
Q1
$886K Sell
6,858
-1,683
-20% -$203K 0.02% 617
2023
Q4
$977K Sell
8,541
-355
-4% -$35.4K 0.02% 564
2023
Q3
$810K Buy
+8,896
New +$918K 0.03% 569

Other funds holding XYL

Vident Advisory's XYL Position: Q1 2026 in Review

Vident Advisory increased its Xylem (XYL) stake by 210% in Q1 2026, buying an estimated $2.69M and bringing the position to 30,300 shares worth $3.62M. The position accounts for 0.03% of the portfolio, ranked #442.

Vident Advisory first reported a position in XYL in Q3 2023 and has held it in 11 quarters since. 1,107 funds tracked by Wall St. Rank hold XYL as of Q1 2026.

  • Vident Advisory held 30,300 shares of Xylem worth $3.62M as of Q1 2026.
  • Vident Advisory bought 20,537 Xylem shares in Q1 2026, an estimated $2.69M.
  • Xylem made up 0.03% of Vident Advisory's portfolio in Q1 2026, its #442 holding.
  • Vident Advisory first reported a position in Xylem in Q3 2023 and has held it in 11 quarters since.
  • 1,107 funds tracked by Wall St. Rank held Xylem as of Q1 2026.

Based on Vident Advisory's 13F filing for Q1 2026, filed 15 May 2026.